AUSTIN, Texas --(BUSINESS WIRE)--Dec. 11, 2019-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will

Company initiates Phase 1 clinical trial of Voriconazole Inhalation Powder, to treat invasive pulmonary aspergillosis (IPA) Successfully completes $24 million initial public offering of common stock AUSTIN, Texas --(BUSINESS WIRE)--Dec. 9, 2019-- TFF Pharmaceuticals, Inc.

First clinical study in healthy subjects of a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation Invasive Pulmonary Aspergillosis is a severe fungal pulmonary disease with a mortality rate that can reach 90 percent¹ in some patient populations AUSTIN, Texas --(BUSINESS WIRE)--Nov.